Prevention of drug-induced liver injury in patients with pulmonary tuberculosis and chronic hepatitis C

Author(s):  
Diana Ivanova ◽  
Sergey Borisov ◽  
Dmitriy Kudlay ◽  
Nicolay Nikolenko ◽  
Ludmila Slogotskaya ◽  
...  
2015 ◽  
Vol 45 (10) ◽  
pp. E156-E160 ◽  
Author(s):  
Akira Okajima ◽  
Kanji Yamaguchi ◽  
Hiroyoshi Taketani ◽  
Tasuku Hara ◽  
Hiroshi Ishiba ◽  
...  

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Shih Yea Sylvia Wu ◽  
Bridget Faire ◽  
Edward Gane

VIEKIRA PAK (ritonavir-boosted paritaprevir/ombitasvir and dasabuvir) is an approved treatment for compensated patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection. This oral regimen has minimal adverse effects and is well tolerated. Cure rates are 97% in patients infected with HCV GT 1a and 99% in those with HCV GT 1b. We report the first case of life-threatening allergic pneumonitis associated with VIEKIRA PAK. This unexpected serious adverse event occurred in a 68-year-old Chinese female with genotype 1b chronic hepatitis C and Child-Pugh A cirrhosis. One week into treatment with VIEKIRA PAK without ribavirin, she was admitted to hospital with respiratory distress and acute kidney injury requiring intensive care input. She was initially diagnosed with community acquired pneumonia and improved promptly with intravenous antibiotics and supported care. No bacterial or viral pathogens were cultured. Following complete recovery, she recommenced VIEKIRA PAK but represented 5 days later with more rapidly progressive respiratory failure, requiring intubation and ventilation, inotropic support, and haemodialysis. The final diagnosis was drug induced pneumonitis.


2015 ◽  
Vol 3 (3) ◽  
pp. 151-154
Author(s):  
Kyrillus S. Shohdy ◽  
Rasmia M. El Gohary

Background: Cases of drug induced liver injury still perplex gastroenterologists due to its wide range of presentations that mimic acute and chronic liver conditions. Moreover, matters get complicated when clinicians face the possibility of drug-induced injury in the presence of pre-existing chronic liver disease. Case: A 69 year-old male who was recently discovered to have a hepatitis C viral infection presented with acute manifestations (mixed cholangio-hepatocellular injury) not fully explained by the underlying chronic disease, we suspected an idiosyncratic reaction from an esterified anabolic androgen. His manifestations have appeared acutely after the drug intake and include acute onset of jaundice, abdominal pain, pruritus and choluria. He was improving on drug discontinuity and conservative measures during his brief hospital stay. Conclusion: The underlying chronic disease constitutes a dilemma in diagnosis of superimposed drug-induced liver injury, as the proof of causality is a daunting task. In such cases, it is tempting to link such new emerging manifestations to be a flare-up of the underlying chronic disease rather than to the drug. However, certain clues helped to point this clinical presentation towards a drug-induced liver injury


Author(s):  
J. Neuberger

Case History—A 22 yr old man, being treated for pulmonary tuberculosis, now presenting with confusion and jaundice. Drug-induced liver injury (DILI) is relatively uncommon but can very rarely be fatal. Almost all patterns of liver disease can be induced by drugs, and some drugs may be associated with more than one type of reaction. Some cases of DILI have a genetic component. Most cases present with jaundice and/or hepatitis....


2017 ◽  
Vol 15 (1) ◽  
pp. 21
Author(s):  
MahmoudH Hemida ◽  
ShaabanS Alazhari ◽  
AhmedEl Borae Kabil ◽  
Abd El HalimAssem Elsherif ◽  
MohamedAbd El Hameed Khedr

2010 ◽  
Vol 61 (4) ◽  
pp. 323-329 ◽  
Author(s):  
Wan Beom Park ◽  
Won Kim ◽  
Kook Lae Lee ◽  
Jae-Joon Yim ◽  
Moonsuk Kim ◽  
...  

2011 ◽  
Vol 140 (5) ◽  
pp. S-951
Author(s):  
R Kenton Devine ◽  
Hejun Yuan ◽  
Mamta K. Jain ◽  
Corron M. Sanders ◽  
Nahid Attar ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document